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Abstract 
Hippocampal abnormalities are believed to increase the risk of cognitive decline in diabetic 
patients. The underlying mechanism is unknown, but both hyperglycemia and oxidative stress 
have been implicated. Cellular stresses induce expression of heat shock protein 25 (HSP25) and this 
results in cytoprotection. Our aim was to assess hippocampal expression of HSP25 in experimental 
diabetes. Mice were rendered diabetic by streptozotocin injection. Ten weeks after diabetes onset 
hippocampal HSP25 expression was studied by immunoblotting and immunohistochemistry (IHC). 
Expression of glial fibrillary acidic protein (GFAP), nitrotyrosine, iNOS, HSP72, HSP90, and 
Cu/Zn superoxide dismutase (SOD) was assessed by either IHC or immunoblotting, Cu/Zn-SOD 
activity by enzymatic assay, and malondialdehyde (MDA) content by colorimetric assay. 
Hippocampal HSP25 was significantly increased in diabetic as compared to non-diabetic animals 
and localised predominantly within the pyramidal neurons layer of the CA1 area. This was 
paralleled by overexpression of nitrotyrosine, iNOS, SOD expression/activity, and enhanced MDA 
content. In experimental diabetes, HSP25 is overexpressed in the CA1 pyramidal neurons in parallel 
with markers of oxidative stress. 
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Introduction 
Multiple organ systems are adversely affected by diabetes, including the brain, which undergoes 
changes that may increase the risk of cognitive decline (Ryan et al., 1993; Ott et al., 1999; Rstow, 
2004). Studies in experimental diabetes have demonstrated progressive astrogliosis, pyramidal 
neuron apoptosis, altered synaptic plasticity, and reduced dendritic complexity within the 
hippocampus (Magariños and McEwen, 2000; Saravia et al., 2002; Valastro et al., 2002). The 
underlying mechanisms of these abnormalities are unknown; however, both hyperglycemia and 
oxidative stress have been implicated (Mastrocola et al., 2005; Nishikawa et al., 2000). 
Heat Shock Proteins (HSPs) are ubiquitous, highly evolutionary conserved intracellular proteins 
(Ellis and van der Vies, 1991). Thermal, oxidative, hemodynamic, osmotic, and hypoxic stresses 
induce HSPs expression, and this stress response results in cytoprotection (Ellis and van der Vies, 
1991; Feder and Hofmann, 1999). Specifically, HSPs prevent nonspecific protein assembly, assist 
in denatured protein refolding, and interfere with proapoptotic pathways (Yenari et al., 2005). 
Studies on the expression of HSPs in the diabetic hippocampus have shown that HSP60, a 
mitochondrial-specific molecular chaperon, is overexpressed in the hippocampal CA1 region and 
that HSP60 expression strongly correlates with that of superoxide dismutase (SOD) (Yuan et al., 
2006), a marker of mitochondrial oxidative stress. By contrast, no abnormalities in HSP70 
expression were observed (Guven et al., 2009). 
HSP25 is a chaperone, binds to F-actin, and protects cells from both oxidative stress and apoptosis 
(Mehlen et al., 1997; Sanz et al., 2001). In addition, HSP25 interacts with HSP90 and synergizes 
with HSP72 in preventing neural cell death (Patel et al., 2005). HSP25 is weakly expressed in the 
normal hippocampus, but strongly induced in hippocampal neurons exposed to thermal stress 
(Kirbach and Golenhofen, 2011). Recent studies have shown that HSP25 expression is enhanced in 
the retina and the kidney (Barutta et al., 2008; Pinach et al., 2011) from mice made diabetic with 
streptozotocin (STZ), an antibiotic that causes pancreatic β-cell destruction, resulting in a state of 
insulin-dependent type 1 diabetes mellitus. Whether HSP25 is also altered in the brain, another 
important target organ of diabetes-induced injury, remains unknown. 
The aim of the present study was to assess HSP25 expression in the hippocampus of streptozotocin-
induced diabetic mice in parallel with markers of oxidative stress. 
Experimental procedures 
Materials 
All materials were purchased from Sigma (St. Louis, MO) unless otherwise stated. 
Animals and induction of diabetes  
Eight-week-old male C57BL6 mice from Jackson Laboratories (Bar Harbor, ME) were used in the 
present study. All animal procedures were in accordance with the Italian law (D.L.116/1992) and 
animals were maintained on a normal diet under standard animal house conditions. Diabetes was 
induced by intraperitoneal injections of STZ in citrate buffer, pH 4.5 (55 mg/kg body wt/day), 
delivered in five consecutive daily doses. Mice sham injected with sodium citrate buffer were used 
as controls. Diabetes onset was confirmed by blood glucose levels >250 mg/dl 4 weeks after the 
first dose of STZ. After 10 weeks of experimental diabetes, mice were euthanized by decapitation. 
Brain hemispheres were fixed in 4% neutral buffered formaldehyde and then paraffin embedded for 
light microscopy. The hippocampus was isolated, frozen in N2, and stored at -80°C for protein 
analysis.  
Metabolic and physiological parameters 
Before euthanasia blood samples were taken via saphenous vein puncture on alert 4 hours fasted 
animals, and glucose levels measured using a glucometer (Accu-chek; Roche Applied Science). 
Glycated hemoglobin was measured in whole blood samples obtained at the time of killing by 
quantitative immunoturbidimetric latex determination (Sentinel Diagnostic, Milan, Italy). 
Immunohistochemistry 
Immunohistochemical staining was performed on 4-µm paraffin sections of fixed tissue. Briefly, 
sections were dewaxed, rehydrated, and immersed in 0.01M citrate buffer pH 6.0 at 100°C for 
antigen retrieval. Endogenous peroxidase activity was quenched by incubation with 3% H2O2. 
Endogenous avidin-binding activity was inhibited by sequential treatment with avidin-biotin, and 
non-specific binding sites blocked with 3% BSA. For immunodetection, sections were incubated 
overnight with mouse anti-glial fibrillary acidic protein (GFAP, Calbiochem, Darstadt, Germany), 
rabbit anti-HSP25 (Stressgen, Ann Arbor, MI, USA), or rabbit anti-nitrotyrosine (anti-N-Tyr 
Abcam, Cambridge, UK) antibodies, then the specific staining was detected using the high sensitive 
Labeled StreptAvidin Biotin (LSAB) + system-HRP (Dako, Glostrup, Denmark) that uses a refined 
avidin-biotin technique in which a biotinylated secondary antibody reacts with several peroxidase-
conjugated streptavidin molecules. Sections were counterstained with Mayer's hemallume and 
visualized with an epifluorescence microscope (Olympus-Bx4I) connected by a photographic 
attachment (Carl Zeiss, Oberkochen, Germany). For each antibody, a negative control was included 
in which the primary antibody was replaced with a non-immune isotypic control antibody. In 
semiquantitative immunohistochemical analysis, the cellular area of nucleated positive cells with a 
staining intensity over an established threshold was calculated by a computer-aided image-analysis 
system (Axiovision 4.7; Carl Zeiss) on digital images of hippocampal sections, as previously 
described (Saravia et al., 2002). Results were then expressed as percentage increase over non-
diabetic controls. In addition, GFAP staining was also calculated as the number of GFAP positive 
cells per area (65x103 μm2). Evaluations were performed by two independent investigators in a 
blinded fashion.  
Cu/Zn-SOD activity 
Cu/Zn-SOD activity was evaluated in cytosolic hippocampal extracts by a kinetic enzymatic 
commercial assay kit (Cayman Chemical, Ann Arbor, MI, USA), following manufacturer’s 
instructions. 
Malondialdehyde measurement 
Malondialdehyde (MDA), a marker of lipid peroxidation, was measured by a commercial 
colorimetric assay kit (BioVision, Milpitas, USA) following manufacturer’s instructions. MDA 
levels in hippocampal sample homogenates were expressed as nanomoles of MDA per milligram of 
protein. 
Immunofluorescence 
Expression of Cu/Zn SOD was assessed by indirect immunofluorescence using a sheep anti-mouse 
primary antibody (Calbiochem-Merck, Milan, Italy) and a FITC-conjugated donkey anti-sheep 
secondary antibody (Dako). Sections were examined using an Olympus epifluorescence microscope 
(Olympus Bx4I) and digitised with a high resolution camera (Carl Zeiss). 
Double immunofluorescence 
Double immunofluorescence was performed for HSP25 and either Cu/Zn-SOD or GFAP on 
hippocampal sections. After blocking, sections were incubated with either an anti-Cu/Zn-SOD 
antibody or an anti-GFAP antibody for 1 hour, followed by a labelled secondary antibody (Cu/Zn-
SOD: FITC-conjugated donkey-anti sheep antibody; GFAP: TRITC-conjugated goat anti-mouse 
antibody). After washing, sections were incubated with an anti-HSP25 antibody for 18 h at 4°C, 
followed by 1 h incubation with a biotinylated swine anti-rabbit IgG (Dako) and then with 
FITC/Alexa 555-conjugated streptavidin (Invitrogen, Milan, Italy). Sections were examined using 
an Olympus epifluorescence microscope (Olympus Bx4 I) with photographic attachment (Carl 
Zeiss). The images were colour-combined and assembled into photomontages by using Adobe 
Photoshop (Universal Imaging, West Chester, PA). 
Protein Extraction 
For total protein extraction isolated hippocampal tissue was homogenised in a modified RIPA 
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 
0.1% SDS, 1 mM EDTA, 1 µg/mL leupeptin, 1 µg/ml aprotinin, 1 mM PMSF). Lysates were then 
centrifuged at 10,000 g for 40 min at 4° and protein concentration measured by DC protein (Bio-
Rad Laboratories, Hercules, CA, USA). Cytosolic and nuclear extracts were prepared as previously 
described (Collino et al, 2006 Collino et al, 2009). Briefly, tissues were homogenized at 10% 
(wt/vol) in a Potter Elvehjem homogenizer (Wheaton, Millville, NJ) using a homogenization buffer 
containing 20 mM HEPES (pH 7.9), 1 mM MgCl2, 0.5 mM EDTA, 1% Nonidet P-40, 1 mM 
EGTA, 1 mM DTT, 0.5 mM PMSF, 5 μg/ml aprotinin, and 2.5 μg/ml leupeptin. Homogenates were 
centrifuged at 1000 × g for 5 min at 4 C. Supernatants were removed and centrifuged at 105,000 × g 
at 4 C for 40 min to obtain the cytosolic fraction. The pelleted nuclei were resuspended in extraction 
buffer containing 20 mM HEPES (pH 7.9), 1.5 mM MgCl2, 300 mM NaCl, 0.2 mM EDTA, 20% 
glycerol, 1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 5 μg/ml aprotinin, and 2.5 μg/ml leupeptin and 
incubated on ice for 30 min for high-salt extraction, followed by centrifugation at 15,000 × g for 20 
min at 4 C. The resulting supernatants containing nuclear proteins were carefully removed and 
stored at −80 C. 
Immunoblotting 
Equal amounts of total protein were separated on a 10% SDS-polyacrylamide gel, then transferred 
to nitrocellulose membrane (Amersham Biosciences, Braunschweig, Germany). Following blocking 
of non-specific sites with 5% non-fat milk, membranes were probed with anti-HSP25, anti-HSP72 
(Stressgen, Ann Arbor, MI, USA), anti-HSP90 (Stressgen, Ann Arbor, MI, USA), anti-GFAP, anti-
nitrotyrosine, anti-iNOS (Cell Signalling, MI, Italy), anti-USF2 (Santa Cruz, CA, USA) antibodies 
overnight at 4°C. After washing, a secondary HRP-linked (Amersham) antibody was added. 
Immunoreactive bands were detected bySuperSignal West Femto chemiluminescence (Pierce, 
Rockford, IL, USA), visualised on a Gel-Doc system (Bio-Rad), and quantified by image J 
software. Tubulin (Santa Cruz Biotechnology) was used as internal control. In addition, USF-2 and 
β-tubulin serve as markers of nuclear and cytosolic fractions, respectively. 
Statistical Analysis 
The results are expressed as means ± SD. Comparisons were performed by unpaired two-tailed 
Student’s t-test. P<0.05 was considered statistically significant. 
Results 
Metabolic and physiological parameters 
As shown in Table 1, after 10 weeks of diabetes both blood glucose and glycated haemoglobin 
levels were significantly higher in diabetic (DM) than in non-diabetic (ND) mice. Furthermore, 
compared to sham-injected control animals, diabetic mice showed a significant decrease in body 
weight. 
Hippocampal astrogliosis 
GFAP protein expression was studied in the hippocampus from both control and diabetic mice by 
western blotting. Immunoblots showed a band migrating at ~50 kDa, corresponding to the reported 
molecular weight of GFAP and densitometric analysis demonstrated that GFAP protein expression 
was significantly increased in the diabetic mice (Figure 1I), indicating the presence of hippocampal 
astrogliosis in experimental diabetes. To evaluate the distribution of GFAP staining within the 
hippocampus, GFAP expression was also assessed by immunohistochemistry. Specificity of the 
antibody binding was confirmed by staining disappearance when the antibody was replaced with a 
non-immune isotype control antibody (Figure 1A). Consistent with our immunoblotting results, 
hippocampal positive staining for GFAP appeared greater in diabetic mice as compared to control 
animals in all hippocampal subfields, though the difference was particularly marked in the stratum 
lacunosum-moleculare (Figure 1 B,C). As shown in higher magnification images, GFAP positive 
staining in the CA1 area was greater in diabetic mice than in controls (Figure 1 D,E), but in diabetic 
animals there were no differences in GFAP staining between CA1 and CA3 areas (Figure 1G,H). 
Semiquantitative analysis performed in the CA1 area showed that diabetic mice had a significant 
2.5 fold increase of the GFAP-positive cellular area (Figure 1F) and a significant 3-fold increase in 
the number of GFAP positive cells (ND: 23 ± 1,05 vs DM 61 ± 0.79; p< 0.001). 
Hippocampal HSP25 expression in experimental diabetes 
To establish whether HSP25 expression is modulated by diabetes, we studied HSP25 protein 
expression in total hippocampus from both diabetic and control mice by western blotting. Total 
HSP25 protein expression was greater in diabetic mice and in densitometric analysis we found a 
significant 2.8-fold increase of HSP25 expression in diabetic animals as compared to controls 
(Figure 2A). On the contrary, hippocampal HSP72 and HSP90 expression was similar in diabetic 
and control animals (Figure 2B,C). 
Distribution of HSP25 staining in the diabetic hippocampus 
To assess HSP25 distribution within the hippocampus, we studied HSP25 expression in 
hippocampal sections by immunohistochemistry. Staining for HSP25 was enhanced in diabetic 
mice and localised predominantly to the CA1 pyramidal neurons layer (Figure 2 D,E and GH). 
Antibody specificity was confirmed by disappearance of the signal when the antibody was replaced 
with a non-immune isotype control antibody (Figure 2 F,I). Double immunofluorescence for both 
HSP25 (Figure 2J) and GFAP (Figure 2K) confirmed the presence of a predominant HSP25 
staining in the pyramidal neurons layer (Figure 2L), but revealed that some GFAP-positive 
activated astrocytes (Figure 2K) also stained positively for HSP25 (Figure 2L). At high 
magnification, HSP25 and GFAP exhibited differences in their spatial distribution within 
astrocytes. GFAP localised mainly in the cellular processes, while HSP25 was observed 
predominantly in the somata (Figure 2L insert). 
Markers of oxidative stress are enhanced in the diabetic hippocampus 
As oxidative stress is a known inducer of HSP25, an array of oxidative stress markers was also 
studied in the hippocampus from control and diabetic mice. As shown in Figure 3, in the diabetic 
hippocampus, there was a significant increase in nitrotyrosine staining, as assessed by both 
immunohistochemistry (Figure 3A,B) and immunoblotting (Figure 3C), that was paralleled by 
iNOS overexpression (Figure 3D). Hippocampal content of MDA, a marker of lipid peroxidation, 
was significantly higher in diabetic animals than in controls (Figure 3 E). Finally, in diabetic mice 
we also observed an enhanced immunofluorescent staining for Cu/Zn SOD (Figure 3F,G) and a 
significant increased in hippocampal SOD enzymatic activity (Figure 3H). Double-labelling 
immunofluorescence showed that within the pyramidal neurons layer the positive staining for 
Cu/Zn SOD (Figure 3J) and HSP25 (Figure 3I) appears to localize to the same cell. However, 
overlapping was very modest as Hsp25 showed a more nuclear localization, whereas Cu/Zn SOD 
was predominantly localised in the perinuclear area (Figure 3K). 
Intracellular distribution of HSP25 in the diabetic hippocampus 
To investigate the intracellular distribution of HSP25, western blotting analysis was performed 
separately for nuclear and cytosolic hippocampal protein extracts. USF2, a nuclear marker, and α-
tubulin, a cytosolic marker, were used to confirm nuclear and cytosolic fraction purity (Figure 4A). 
As shown in Figure 4B, in diabetic mice HSP25 expression increased significantly in both the 
cytosolic and the nuclear fractions. However, HSP25 upregulation was greater in protein extracts 
from the nuclei, suggesting that HSP25 overexpression was paralleled by nuclear translocation 
(Figure 4B).  
Discussion 
In this study we have provided evidence that in experimental diabetes HSP25 is overexpressed in 
the hippocampus, predominantly in CA1 pyramidal neuron layer, in parallel with enhanced 
oxidative stress and astrogliosis. In hippocampal protein extracts HSP25 expression was greater in 
diabetic than in control mice as assessed by immunoblotting. On the contrary, no difference were 
observed in HSP72 and HSP90, suggesting that diabetes has a specific effect on HSP25. Previous 
studies have shown that hippocampal HSP25 is overexpressed in response to hyperthermia, 
preconditioning, ischemia, epileptic seizure (Benn et al., 2002; Franklin et al., 2005; Kirbach and 
Golenhofen, 2011), but this is the first evidence of HSP25 overexpression in the hippocampus in 
experimental diabetes. In diabetic mice, HSP25 was predominantly expressed by the pyramidal 
neurons of the CA1 region, as assessed by immunohistochemistry. This is not surprising as the CA1 
region is highly sensitive to oxidative damage due to high anion superoxide production by CA1 
pyramidal neurons (Wang et al., 2005). A HSP25 immunoreactivity of CA1 pyramidal neurons has 
been previously reported in vivo (Kato et al., 1999). Furthermore, a recent study has shown that 
cultured hippocampal neurons overexpress HSP25 in response to heat stress, suggesting a direct 
cytoprotective role of HSP25 in this cell type (Kirbach and Golenhofen, 2011). 
Consistent with a previous report (Saravia et al., 2002), we found that expression of GFAP, a 
reliable marker of reactive astrocytes, was enhanced in the hippocampus from diabetic mice, 
confirming the presence of astrogliosis in experimental diabetes. The difference in GFAP staining 
between diabetic and control mice was particularly marked in the stratum lacunosum1 moleculare. 
HSP25, however, was only sporadically expressed by activated astrocytes. At variance, in 
experimental models of ischemia, epilepsy, and hyperthermia, HSP25 expression is restricted to 
reactive astrocytes (Benn et al., 2002; Franklin et al., 2005; Kirbach and Golenhofen, 2011). The 
underlying mechanism of this discrepancy is unclear; however, it is possible that the predominant 
HSP overexpression in CA1 pyramidal neurons is a specific feature of diabetes-induced damage. In 
line with this hypothesis, hippocampal HSP60 is induced in CA1 pyramidal neurons in STZ-
induced diabetic animals (Yuan et al., 2006), while is overexpressed by astrocytes after transient 
ischemia (Hwang et al., 2007). 
In diabetic mice hippocampal HSP25 overexpression occurred not only in the cytosol, but also in 
the nuclei. This finding is of functional relevance as in cultured hippocampal cells HSP25 nuclear 
translocation is important for HSP25 protective effect against DNA fragmentation and in conferring 
resistance to cellular stresses (Geum et al., 2002). Furthermore, in cultured neurons, nuclear HSP25 
potentiates SP1-dependent neurotrophic gene transcription, suggesting that HSP25 may exert a 
cytoprotective effect also through modulation of transcriptional activity (Friedman et al., 2009). 
The underlying mechanism of HSP25 overexpression is unknown. However, oxidative stress is a 
likely candidate as it is a potent inducer of HSP expression (Calabrese et al., 2003; Mehlen et al., 
1993) and is enhanced in the diabetic hippocampus (Aragno et al., 2005; Mastrocola et al., 2005). 
Alternatively, proteasomal stress can also be implicated as a diabetes-induced insufficiency of the 
proteasome system may triggers a stress response through heat shock factor 1 activation, resulting 
in HSP25 induction (Dantuma et al, 2010). However, lack of HSP72/HSP90 overexpression in our 
model makes less likely this possibility. 
To further explore the role of oxidative stress in diabetes-induced HSP25 hippocampal expression, 
we have also studied an array of oxidative stress markers. Cu/Zn SOD, which catalyzes the 
conversion of superoxide radicals to hydrogen peroxide, represents an important defence against 
superoxide production and an indirect index of  oxidative stress. Consistent with previous results in 
STZ-induced diabetic rats (Huang et al., 1999), we found an increase in Cu/Zn SOD both 
expression and activity in the diabetic hippocampus. In addition, we found that SOD was 
predominantly expressed in the CA1 pyramidal neuron layer and that SOD and HSP25 localize to 
the same cell, though with a diverse intracellular distribution. A recent report has demonstrated that, 
in the context of global cerebral ischemia, hyperglycemia can exacerbate superoxide production in 
hippocampal CA1 neurons, suggesting hyperglycemia as a possible mechanism of SOD induction 
(Muranyi and Li, 2005). 
The presence of nitrotyrosine on proteins is a marker of in vivo peroxynitrite formation from nitric 
oxide and superoxide. An increased nitrotyrosine expression in CA1 pyramidal neurons has been 
previously demonstrated in foetuses exposed to hyperglycemia because of maternal diabetes 
(Hockett et al., 2004), but our work provides the first evidence of enhanced hippocampal 
nitrotyrosine in an adult model of experimental diabetes and identifies the CA1 pyramidal neuron 
layer as a specific site of enhanced peroxynitrite formation. Of interest a recent study has shown a 
strong nitrotyrosine immunoreactivity of CA1 pyramidal neurons in mice expressing a mutated 
form of SOD (Cha et al., 2000), providing evidence of a causal link between oxidative stress and 
nitrotyrosine expression in this region. On the other hand, in our study we also found that iNOs 
protein expression was greater in diabetic than in control mice. Therefore, increased levels of 
nitrotyrosine containing proteins may, at least in part, reflect an increased NO production likely 
secondary to diabetes-induced endothelial dysfunction (Nagareddy et al., 2005). 
Reactive oxygen species degrade polyunsaturated lipids, forming MDA. This reactive aldehyde, 
which can cause cellular toxic stress, is thus used as a marker of oxidative stress and lipid 
peroxidation. In our study, hippocampal content of MDA was found significantly enhanced in 
diabetic mice as compared to controls. This finding is in agreement with previous studies (Grillo et 
al., 2003; Cosar et al., 2008). Furthermore, it provides a more convincing and direct evidence of the 
presence of enhanced oxidative stress in our experimental model. HSP25 decreases reactive oxygen 
species and enhances levels of glutathione, the most important intracellular antioxidant (Mehlen et 
al., 1997; Preville et al., 1999). Furthermore, therapeutic strategies, leading to HSP25 upregulation, 
diminish hippocampal neuron apoptosis in rodents (Akbar et al., 2003; An et al., 2009; Jin et al., 
2006). Therefore, the upregulation of HSP25, herein reported, may represent a protective 
mechanism against diabetesinduced oxidative stress and neuronal death. However, no causal 
relationship can be drawn from morphological studies and further investigations are required to 
establish whether HSP25 is solely an indicator of oxidative stress or plays a role in neuroprotection 
of the diabetic hippocampus. 
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Figure Legends 
Figure 1. Expression of GFAP in the hippocampus from control and diabetic mice. 
GFAP expression was assessed by immunohistochemistry in hippocampal sections from 
nondiabetic (ND n=4) and diabetic (DM n=4) mice. Representative images (x40) of the whole 
hippocampus: (A) negative control, (B) non-diabetic mice, (C) diabetic mice. Images (x200) of the 
hippocampal CA1 region in (D) non-diabetic and (E) diabetic mice. Results of semiquantitative 
analysis in the CA1 region are shown in the graph (F) (*p<0.001 DM vs ND). Images (x200) 
comparing hippocampal CA1 (G) and CA3 (H) regions in diabetic mice. GFAP protein expression 
was assessed by immunoblotting in total hippocampal protein extracts. A representative 
immunoblot and results of densitometry analysis are shown (I). Tubulin was used as internal control 
(n=4; *p<0.01 DM vs ND). 
Figure 2. HSP25 expression and localisation in the diabetic hippocampus. 
HSP25 protein expression were studied by immunoblotting on hippocampal protein extracts from 
non-diabetic (ND) and diabetic mice (DM). Tubulin was used as internal control. A representative 
immunoblot and results of densitometry analysis are shown (A) (n=4; *p<0.01 DM vs. ND). Protein 
expression of both HSP72 and HSP90 was also assessed in total protein hippocampal extracts 
(B,C). HSP25 expression was analyzed by immunohistochemistry on hippocampal sections from 
non-diabetic mice (ND n=4) (D,G) and diabetic (DM n=4) (E,H) mice. Specificity of antibody 
binding was confirmed with a non-immune isotype control antibody (F,I) (D-F: 40X and G-I: 400X 
magnification). Double immunofluorescence for HSP25 (J) and GFAP (K) showed no 
colocalisation (L), except for sporadic astrocytes (L insert). 
Figure 3. Markers of oxidative in the diabetic hippocampus. 
A number of oxidative stress markers were assessed in the hippocampus from non-diabetic (ND 
n=4) and diabetic (DM n=4) mice. Representative immunohistochemical images of nitrotyrosine 
(N-tyr) in hippocampal sections from ND (A) and DM mice (B) (magnification 400X). 
Immunoblots and results of densitometry analyses of N-tyr (C) and iNOS (D) protein expression in 
hippocampal protein extracts from ND and DM mice (n=4, *p 0.01 DM vs ND, tubulin: internal 
control). Malondialdehyde (MDA) levels (E) in hippocampal homogenates from ND and DM mice 
(n=4, *p<0.001 DM vs ND). Cu/Zn superoxide dismutase (SOD) both staining (F,G) and activity 
(H) in the hippocampus from ND (F) and DM mice (G), assessed by immunofluorescence 
(magnification 400X) and enzymatic assay (n=4, *p<0.05 DM vs ND), respectively. Double 
immunofluorescence for HSP25 (I) and SOD (J) and merged image (K) in hippocampal sections 
from DM mice. 
Figure 4. Intracellular HSP25 hippocampal distribution 
HSP25 protein expression was studied in hippocampal both cytosolic and nuclear protein extracts 
from non-diabetic (ND n=3) and diabetic (DM n=3) mice by immunoblotting. Tubulin was used as 
internal control. USF2, a nuclear marker, and beta-tubulin, a cytosolic marker, were used to confirm 
purity of nuclear and cytosolic extracts (A). Representative immunoblots (B) and results of 
densitometry analysis (C) are shown (*P<0.05; #P<0.01 DM vs. ND). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table.1 Metabolic and physiologic parameters of control and diabetic mice 
 
Body weight           
(grams) 
Blood Glucose            
(mmol/L) 
Glycated Hb                 
(%) 
Control (6) 29.08 ± 0.78 4.28 ± 0.53 5.94 ± 1.16 
Diabetes (6) 24.64 ± 0.93* 20.78 ± 2.95* 11.19 ± 2.37* 
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